Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population : The IgA and IgG titers increased earlier than the IgM titers
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved..
To better understand the immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with COVID-19, it is important to investigate the kinetics of the antibody responses and their associations with the clinical course in different populations, since there seem to be considerable differences between Western and Asian populations in the clinical features and spread of COVID-19. In this study, we serially measured the serum titers of IgM, IgG and IgA antibodies generated against the nucleocapsid protein (NCP), S1 subunit of the spike protein (S1), and receptor-binding domain in the S1 subunit (RBD) of SARS-CoV-2 in Japanese individuals with COVID-19. Among the IgM, IgG, and IgA antibodies, IgA antibodies against all of the aforementioned viral proteins were the first to appear after the infection, and IgG and/or IgA seroconversion often preceded IgM seroconversion. In regard to the timeline of the antibody responses to the different viral proteins (NCP, S1 and RBD), IgA against NCP appeared than IgA against S1 or RBD, while IgM and IgG against S1 appeared earlier than IgM/IgG against NCP or RBD. The IgG responses to all three viral proteins and responses of all three antibody classes to S1 and RBD were sustained for longer durations than the IgA/IgM responses to all three viral proteins and responses of all three antibody classes to NCP, respectively. The seroconversion of IgA against NCP occurred later and less frequently in patients with mild COVID-19. These results suggest possible differences in the antibody responses to SARS-CoV-2 antigens between the Japanese and Western populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
International immunopharmacology - 103(2022) vom: 25. Feb., Seite 108491 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurano, Makoto [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 28.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2021.108491 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334904544 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334904544 | ||
| 003 | DE-627 | ||
| 005 | 20231225224710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2021.108491 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM334904544 | ||
| 035 | |a (NLM)34954559 | ||
| 035 | |a (PII)S1567-5769(21)01127-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurano, Makoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population |b The IgA and IgG titers increased earlier than the IgM titers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 28.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a To better understand the immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with COVID-19, it is important to investigate the kinetics of the antibody responses and their associations with the clinical course in different populations, since there seem to be considerable differences between Western and Asian populations in the clinical features and spread of COVID-19. In this study, we serially measured the serum titers of IgM, IgG and IgA antibodies generated against the nucleocapsid protein (NCP), S1 subunit of the spike protein (S1), and receptor-binding domain in the S1 subunit (RBD) of SARS-CoV-2 in Japanese individuals with COVID-19. Among the IgM, IgG, and IgA antibodies, IgA antibodies against all of the aforementioned viral proteins were the first to appear after the infection, and IgG and/or IgA seroconversion often preceded IgM seroconversion. In regard to the timeline of the antibody responses to the different viral proteins (NCP, S1 and RBD), IgA against NCP appeared than IgA against S1 or RBD, while IgM and IgG against S1 appeared earlier than IgM/IgG against NCP or RBD. The IgG responses to all three viral proteins and responses of all three antibody classes to S1 and RBD were sustained for longer durations than the IgA/IgM responses to all three viral proteins and responses of all three antibody classes to NCP, respectively. The seroconversion of IgA against NCP occurred later and less frequently in patients with mild COVID-19. These results suggest possible differences in the antibody responses to SARS-CoV-2 antigens between the Japanese and Western populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IgA | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a IgM | |
| 650 | 4 | |a Japanese population | |
| 650 | 4 | |a Kinetics of antibody responses | |
| 650 | 4 | |a Nucleocapsid protein | |
| 650 | 4 | |a Receptor-binding domain | |
| 650 | 4 | |a Spike protein | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 700 | 1 | |a Morita, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoyama, Rin |e verfasserin |4 aut | |
| 700 | 1 | |a Shimura, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Chungen |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Fuzhen |e verfasserin |4 aut | |
| 700 | 1 | |a He, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmiya, Hiroko |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Yoshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshikawa, Naoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nagura, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Okazaki, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Jubishi, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Moriya, Kyoji |e verfasserin |4 aut | |
| 700 | 1 | |a Seto, Yasuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yasui, Fumihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kohara, Michinori |e verfasserin |4 aut | |
| 700 | 1 | |a Wakui, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamura, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kodama, Tatsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yatomi, Yutaka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 103(2022) vom: 25. Feb., Seite 108491 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2022 |g day:25 |g month:02 |g pages:108491 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2021.108491 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2022 |b 25 |c 02 |h 108491 | ||